Philippines

Population 2018  107 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>591 (332–924)</td>
<td>554 (311–866)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>10 (4.1–19)</td>
<td>9.4 (3.8–17)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence</td>
<td>18 (7.7–32)</td>
<td>17 (7.3–30)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>26 (22–30)</td>
<td>24 (20–28)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>0.6 (0–4.2)</td>
<td>0.57 (0–4)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018
New cases: 1.7% (1.1–2.5)
Previously treated cases: 16% (19–20)

TB case notifications, 2018
Total new and relapse: 371 668
- % tested with rapid diagnostics at time of diagnosis: 36%
- % with known HIV status: 27%
- % pulmonary: 98%
- % bacteriologically confirmed: 36%
- % children aged 0–14 years: 12%
- % women: 30%
- % men: 58%
Total cases notified: 382 543

Universal health coverage and social protection
TB treatment coverage (notified/estimated incidence), 2018: 63% (40–110)
TB patients facing catastrophic total costs, 2017: 35% (33–37)
TB case fatality ratio (estimated mortality/estimated incidence), 2018: 5% (3–7)

TB/HIV care in new and relapse TB patients, 2018
Patients with known HIV status who are HIV-positive: 1 477 1%
- on antiretroviral therapy: 1 350 91%

Drug-resistant TB care, 2018
% of bacteriologically confirmed TB cases tested for rifampicin resistance **
- New cases: <1%
- Previously treated cases: 24%

Laboratory-confirmed cases*
MDR/RR-TB: 7 276, XDR-TB: 52

Patients started on treatment**
MDR/RR-TB: 6 125, XDR-TB: 52
MDR/RR-TB cases tested for resistance to second-line drugs: 2 095

Treatment success rate and cohort size
New and relapse cases registered in 2017: 91% 315 923
Previously treated cases, excluding relapse, registered in 2017: 82% 9 486
HIV-positive TB cases registered in 2017: 83% 1 258
MDR/RR-TB cases started on second-line treatment in 2016: 58% 5 071
XDR-TB cases started on second-line treatment in 2016: 20% 10

TB preventive treatment, 2018
% of HIV-positive people (newly enrolled in care) on preventive treatment: 52%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 9.4% (8.7–10)

TB financing, 2019
National TB budget (US$ millions): 205
Funding source: 12% domestic, 25% international, 63% unfunded

* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2020-03-09
Data: www.who.int/tb/data